Instruction for use: Isicom

Dosage form: tablets

Active substance: Levodopa + Carbidopa*

ATX

N04BA02 Levodopa and a decarboxylase inhibitor

Pharmacological groups:

Dopaminomimetics in combination

Antiparkinsonics in combination

The nosological classification (ICD-10)

G20 Parkinson's disease: A trembling paralysis; Idiopathic Parkinsonism; Parkinson's disease; Symptomatic Parkinsonism

G21 Secondary Parkinsonism: Medicinal Parkinsonism; Parkinsonism; Parkinsonism symptomatic; Disorders of extrapyramidal system; Parkinson's Syndrome

Composition and release form

1 tablet contains levodopa 0.25 g and carbidopa 0.025 g.

Pharmachologic effect

Mode of action - antiparkinsonian, dopaminomimetic.

Pharmacodynamics

The antiparkinsonian effect is due to the conversion of levodopa to the central nervous system under the influence of dopa-decarboxylase in dopamine. To reduce the side effects caused by the formation of excess dopamine in the peripheral tissues, the drug includes carbidopa, an inhibitor of peripheral dopa-decarboxylase.

Indications of the drug Isicom

Parkinson's disease, Parkinsonism (except for caused by neuroleptics).

Contraindications

Hypersensitivity, expressed violations of the liver, kidneys, cardiovascular and endocrine systems, psychoses, zakratougolnaya glaucoma, melanoma, pregnancy, lactation, children's age.

Side effects

Anorexia, nausea, vomiting, epigastric pain, ulcerogenic effect, orthostatic hypotension, arrhythmias, spontaneous movements, sleep disturbance, agitation, dizziness, depression (rarely), leukopenia, thrombocytopenia.

Dosing and Administration

Inside. Doses are selected strictly individually, the initial dose is 0.15-0.25 g of levodopa and 0.015-0.025 g of carbidopa (1 / 2-1 table). The maximum daily dose for levodopa is 1-4 g.

Storage conditions of the drug Isicom

In the dark place.

Keep out of the reach of children.

Shelf life of the drug Isicom

3 years.

Do not use after the expiry date printed on the package.